Weon-Kyoo You
Executive Vice President & Head, R&D ABL Bio Inc.
Seminars
Tuesday 4th November 2025
Validation of Novel Target Combination for Bispecific ADCs by Increasing Tumor Selectivity & Reducing Off-Target Toxicity
- Exploring bispecific ADCs as an emerging and promising next-generation ADC modality
- Outlining the rationale behind target combinations for bispecific ADC design
- Assessing the preclinical safety and efficacy of bispecific ADCs in comparison to monospecific ADCs for clinical trials
